These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 20861740)

  • 1. Relationship between insulin resistance and C-reactive protein in a patient population treated with second generation antipsychotic medications.
    Kim SH; Reaven G; Lindley S
    Int Clin Psychopharmacol; 2011 Jan; 26(1):43-7. PubMed ID: 20861740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The metabolic effects of antipsychotic medications.
    Newcomer JW; Haupt DW
    Can J Psychiatry; 2006 Jul; 51(8):480-91. PubMed ID: 16933585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic risk during antipsychotic treatment.
    Newcomer JW
    Clin Ther; 2004 Dec; 26(12):1936-46. PubMed ID: 15823759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of antipsychotic medications on appetite, weight, and insulin resistance.
    Deng C
    Endocrinol Metab Clin North Am; 2013 Sep; 42(3):545-63. PubMed ID: 24011886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.
    Henderson DC; Cagliero E; Copeland PM; Borba CP; Evins AE; Hayden D; Weber MT; Anderson EJ; Allison DB; Daley TB; Schoenfeld D; Goff DC
    Arch Gen Psychiatry; 2005 Jan; 62(1):19-28. PubMed ID: 15630069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.
    Newcomer JW
    CNS Drugs; 2005; 19 Suppl 1():1-93. PubMed ID: 15998156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents.
    Klein DJ; Cottingham EM; Sorter M; Barton BA; Morrison JA
    Am J Psychiatry; 2006 Dec; 163(12):2072-9. PubMed ID: 17151157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between body mass index and insulin resistance in patients treated with second generation antipsychotic agents.
    Kim SH; Nikolics L; Abbasi F; Lamendola C; Link J; Reaven GM; Lindley S
    J Psychiatr Res; 2010 Jun; 44(8):493-8. PubMed ID: 19962157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antipsychotic medications: metabolic and cardiovascular risk.
    Newcomer JW
    J Clin Psychiatry; 2007; 68 Suppl 4():8-13. PubMed ID: 17539694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atypical antipsychotics and glucose homeostasis.
    Bergman RN; Ader M
    J Clin Psychiatry; 2005 Apr; 66(4):504-14. PubMed ID: 15816794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Obesity, diabetes, and the metabolic syndrome: new challenges in antipsychotic drug therapy.
    Caballero E
    CNS Spectr; 2003 Nov; 8(11 Suppl 2):19-22. PubMed ID: 14978454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin resistance is associated with C-reactive protein independent of abdominal obesity in nondiabetic Taiwanese.
    Chou HH; Hsu LA; Liu CJ; Teng MS; Wu S; Ko YL
    Metabolism; 2010 Jun; 59(6):824-30. PubMed ID: 20004425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Which comes first: atypical antipsychotic treatment or cardiometabolic risk?
    Stahl SM; Mignon L; Meyer JM
    Acta Psychiatr Scand; 2009 Mar; 119(3):171-9. PubMed ID: 19178394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperglycemia and antipsychotic medications.
    Haupt DW; Newcomer JW
    J Clin Psychiatry; 2001; 62 Suppl 27():15-26; discussion 40-1. PubMed ID: 11806485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacologic and nonpharmacologic strategies for weight gain and metabolic disturbance in patients treated with antipsychotic medications.
    Faulkner G; Cohn TA
    Can J Psychiatry; 2006 Jul; 51(8):502-11. PubMed ID: 16933587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of olanzapine and risperidone on glucose metabolism and insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized 5-month study.
    Smith RC; Lindenmayer JP; Davis JM; Kelly E; Viviano TF; Cornwell J; Hu Q; Khan A; Vaidhyanathaswamy S
    J Clin Psychiatry; 2009 Nov; 70(11):1501-13. PubMed ID: 19814947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effective screening for the metabolic syndrome in patients treated with second-generation antipsychotic medications.
    Straker D; Correll CU; Kramer-Ginsberg E; Abdulhamid N; Koshy F; Rubens E; Saint-Vil R; Kane JM; Manu P
    Am J Psychiatry; 2005 Jun; 162(6):1217-21. PubMed ID: 15930076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse events in children and adolescents treated with antipsychotic medications.
    Jerrell JM; McIntyre RS
    Hum Psychopharmacol; 2008 Jun; 23(4):283-90. PubMed ID: 18302312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents.
    McIntyre RS; Jerrell JM
    Arch Pediatr Adolesc Med; 2008 Oct; 162(10):929-35. PubMed ID: 18838645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-sensitivity C-reactive protein (hs-CRP) levels and its relationship with components of polycystic ovary syndrome in Indian adolescent women with polycystic ovary syndrome (PCOS).
    Ganie MA; Hassan S; Nisar S; Shamas N; Rashid A; Ahmed I; Douhat S; Mudassar S; Jan VM; Rashid F
    Gynecol Endocrinol; 2014 Nov; 30(11):781-4. PubMed ID: 25137507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.